Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Sol Andres

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
BMJ Open|February 5, 2025
HER-SAFE study design: an open-label, randomised controlled trial to investigate the safety of withdrawal of pharmacological treatment for recovered HER2-targeted therapy-related cardiac dysfunctionBenjamin Dowsing, Hakim-Moulay Dehbi, Robin Chung, et al.
Breast Cancer Research and Treatment|April 5, 2021
Incidence of cardiotoxicity and validation of the Heart Failure Association-International Cardio-Oncology Society risk stratification tool in patients treated with trastuzumab for HER2-positive early breast cancerNicolò Matteo Luca Battisti, Maria Sol Andres, Karla A Lee, et al.
European Journal of Heart Failure|August 1, 2024
Cardiovascular toxicities of immune therapies for cancer - a scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-OncologyCarlo Gabriele Tocchetti, Dimitrios Farmakis, Yvonne Koop, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
BMJ Open|February 5, 2025
HER-SAFE study design: an open-label, randomised controlled trial to investigate the safety of withdrawal of pharmacological treatment for recovered HER2-targeted therapy-related cardiac dysfunctionBenjamin Dowsing, Hakim-Moulay Dehbi, Robin Chung, et al.
Breast Cancer Research and Treatment|April 5, 2021
Incidence of cardiotoxicity and validation of the Heart Failure Association-International Cardio-Oncology Society risk stratification tool in patients treated with trastuzumab for HER2-positive early breast cancerNicolò Matteo Luca Battisti, Maria Sol Andres, Karla A Lee, et al.
European Journal of Heart Failure|August 1, 2024
Cardiovascular toxicities of immune therapies for cancer - a scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-OncologyCarlo Gabriele Tocchetti, Dimitrios Farmakis, Yvonne Koop, et al.
Pageof 2